Analytical Data
-
Gene name
TNFRSF11B
- Application
-
Alternative Names
TNFRSF11B；OCIF；OPG；Tumor necrosis factor receptor superfamily member 11B
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00300
-
Expression Region
22-401aa
-
AA Sequence
ETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYYTDSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGLLLTQKGNATHDNICSGNSESTQKCGIDVTLCEEAFFRFAVPTKFTPNWLSVLVDNLPGTKVNAESVERIKRQHSSQEQTFQLLKLWKHQNKDQDIVKKIIQDIDLCENSVQRHIGHANLTFEQLRSLMESLPGKKVGAEDIEKTIKACKPSDQILKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPKTVTQSLKKTIRFLHSFTMYKLYQKLFLEMIGNQVQSVKISCL
-
Molecular Weight
73.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFRSF11B, also known as osteoprotegerin (OPG), is a member of the tumor necrosis factor receptor superfamily that plays a vital role in bone metabolism by regulating the differentiation and survival of osteoclasts, the cells responsible for bone resorption. Its primary function involves binding to receptor activator of nuclear factor-kappa B ligand (RANKL), thus inhibiting RANKL's ability to activate its receptor RANK on osteoclast precursors. This interaction is crucial in maintaining bone density and homeostasis, making OPG a significant target for understanding and treating various bone-related disorders, including osteoporosis, rheumatoid arthritis, and certain cancers that affect bone. The research surrounding recombinant TNFRSF11B protein has gained momentum in recent years due to its potential implications in therapeutic applications. By producing recombinant forms of OPG, researchers aim to explore its pharmacological properties, efficacy, and safety for use in clinical settings. This recombinant protein not only serves as a valuable tool for elucidating the mechanisms of osteoclast regulation but also provides insights into developing novel treatment strategies for conditions characterized by excessive bone resorption. Understanding the structure and function of TNFRSF11B further contributes to the advancement of bone health therapies, paving the way for improved interventions in metabolic bone diseases. As such, ongoing studies into the recombinant production and application of TNFRSF11B are crucial for both basic research and translational medical science.
